Ying Yu Ph.D., Professor
	Laboratory of membrane phospholipid metabolism and cardiovascular diseases E-mail: yuying@@sibs.ac.cn

Education Background & Academic Experience:
Dr. Ying Yu received his Bachelor degree from Medical college of Nanchang University in 1995, then got his Master degree in Tumor Immunology Department in the Medical College in 1998. In 2001, he received his PhD in tumor genetics from Cancer Research Institute in Xiangya Medical School in Central South University. He had his postdoctoral training in Pharmacology Department at University of Pennsylvania from 2002 to 2006, and then worked as Research Associate (2006) and Research Assistant Professor (2009) in the Institution for Translational Medicine and Therapeutics at University of Pennsylvania. He joined the Institute of Nutritional Sciences in 2009.

Research Interests:
Eicosanoids are lipid mediators consisting of prostaglandins (PGs), leukotrienes, lipoxins and the epoxyeicosatrienoic acids. This large class of bioactive lipids is derived from the initial release of polyunsaturated fatty acid from the sn2 position of glycerophospholipids predominantly from cytosolic phospholipase A2 and subsequent conversion by either prostaglandin H synthases-1 and -2 (PGHS-1, PGHS-2; also known as COX-1, COX-2), lipoxygenases or various members of the cytochrome P450 family. Prostaglandins control a vast array of (patho) physiological functions including platelet aggregation, cardiovascular homeostasis, female reproductive function and parturition, as well as renal function and roles in inflammation initiation and resolution through G protein-coupled receptors (GPCRs) or peroxisomal proliferator-activated receptors (PPARs). Non-steroid anti-inflammatory drugs (NSAIDs) inhibit COX-1/COX-2 to block PG products. Recently randomized, placebo-controlled clinical trails showed the 2nd generation NSAIDs-Coxib increased cardiotoxicity and propensity for thrombosis (heart attack and stroke). The research interests in our lab are mainly focusing on COX pathways and their downstream receptors in cardiovascular diseases, aging and diabetes mellitus (DM) by using state-of-the-art mouse models.

Research Team:

Selected Publications:

1. Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010 Feb;61:17-33.

2. Yu Y, Stubbe J, Ibrahim S, Song WL, Symth EM, Funk CD and FitzGerald GA. Cyclooxygenase-2-Dependent Prostacyclin Formation and Blood Pressure Homeostasis. Targeted Exchange of Cyclooxygenase Isoforms in Mice. Circ Res. 2010 Feb 2;106(2):337-345.

3. Yu Y, Ricciotte E, Grosser T, FitzGerald GA. The translational therapeutics of prostaglandin inhibition in atherothrombosis. J Throm Haemost. 2009 Jul; 7: 222-6.

4. Song WL, Paschos G, Fries S, Reily MP, Yu Y, FitzGerald GA. Novel EPA-derived F3-isoprostanes as biomakers of lipid peroxidation. J Biol Chem. 2009 Aug 28; 284(35):23636-43.

5. Seta F, Chung A, Mewburn J, Yu Y, Funk CD. Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol. 2009 Jun; 296(6):R1751-60.

6. Wang D, Patel V, Zhou H, Levin MD, Gao E, Ferrari VA, Lu MM, Xu J, Zhang H, Hui Y, Cheng Y, Petrenko N, Yu Y and FitzGerald GA. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A. 2009 May 5; 106(18):7548-52.

7. Yu Y*, Lucitt M* (Co-first author), Stubble J, Cheng Y, Hansen PB, Jensen BL, Symth E, and FitzGerald GA. Prostaglandin F2a elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7985-90.

8. Smyth E, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009 April; 50:S423-8.

9. Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem. 2008 Jan 11; 283: 1179-1188.

10. Yu Y, Fan J, Hui Y, Rouzer CA, Marnett LJ, Klein-Szanto AJ, FitzGerald GA, Funk CD. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem. 2007 Jan 12; 282: 1498-1506.

11. Yu Y, Funk CD. A novel genetic model of selective COX-2 inhibition: comparison with COX-2 null mice. Prostaglandins Other Lipid Mediat. 2007 Jan; 82: 77-84.